Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CSTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.89
1 Year Target Price $35.89
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.22% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 587.55M USD | Price to earnings Ratio - | 1Y Target Price 35.89 |
Price to earnings Ratio - | 1Y Target Price 35.89 | ||
Volume (30-day avg) 9 | Beta 1.04 | 52 Weeks Range 15.45 - 35.84 | Updated Date 06/30/2025 |
52 Weeks Range 15.45 - 35.84 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.46% | Operating Margin (TTM) -31.74% |
Management Effectiveness
Return on Assets (TTM) -1.8% | Return on Equity (TTM) -1.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 337696036 | Price to Sales(TTM) 1.69 |
Enterprise Value 337696036 | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 0.97 | Enterprise Value to EBITDA 8.28 | Shares Outstanding 28872300 | Shares Floating 26464364 |
Shares Outstanding 28872300 | Shares Floating 26464364 | ||
Percent Insiders 2.98 | Percent Institutions 93.02 |
Analyst Ratings
Rating 3 | Target Price 35.89 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences Inc. was founded in 2005. It is a commercial-stage diagnostics company focused on providing personalized genomic information to improve cancer treatment decisions.
Core Business Areas
- Dermatologic Cancers: Focuses on providing genomic tests for melanoma, cutaneous squamous cell carcinoma, and other skin cancers.
- Other Cancers: Developing and commercializing tests for other cancers, including esophageal cancer.
Leadership and Structure
Derek J. Maetzold is the President and CEO. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A gene expression profile test to predict the risk of metastasis in cutaneous melanoma patients. Estimated 50% of the total addressable market (TAM). Competitors include Myriad Genetics (now part of Labcorp) and Interpace Biosciences.
- DecisionDx-SCC: A gene expression profile test to predict the risk of metastasis in cutaneous squamous cell carcinoma patients. Competitors include virtually none (due to the unique gene panel used by Castle Biosciences Inc.)
- TissueCypher Barrett's Esophagus Assay: A spatial systems biology test to predict the risk of progression to high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus. Competitors include Exact Sciences.
Market Dynamics
Industry Overview
The market for personalized cancer diagnostics is growing, driven by increasing awareness of genomic testing and demand for tailored treatment strategies.
Positioning
Castle Biosciences is positioned as a leader in providing genomic information for dermatologic cancers, with a growing presence in other cancer areas. Its competitive advantage lies in its proprietary tests and clinical validation data.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) for Castle Biosciences' current portfolio of tests is over $2 billion. They aim to capture significant share through expansion into new indications and penetration of existing markets.
Upturn SWOT Analysis
Strengths
- Proprietary genomic tests
- Strong clinical validation data
- Experienced management team
- Established sales and marketing infrastructure
- Focus on unmet medical needs
Weaknesses
- Reliance on single platform for revenue generation
- Dependence on reimbursement from payers
- Limited product portfolio outside dermatology
- Relatively small company size compared to competitors
Opportunities
- Expanding into new cancer indications
- Increasing adoption of genomic testing
- Developing new tests and technologies
- Strategic partnerships and acquisitions
- Expanding international presence
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Technological advancements rendering tests obsolete
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- L
- EXAS
- ILMN
- STVN
Competitive Landscape
Castle Biosciences' competitive advantage lies in its proprietary tests and clinical validation data. Larger competitors have broader product portfolios and greater financial resources.
Major Acquisitions
Myriad Genetics' dermatology business
- Year: 2022
- Acquisition Price (USD millions): 45
- Strategic Rationale: Expanded Castle Biosciences' portfolio of dermatologic diagnostic tests and broadened its market reach.
AltheaDx
- Year: 2021
- Acquisition Price (USD millions): 158.5
- Strategic Rationale: Enhance precision diagnostics in autoimmune and inflammatory diseases with complementary solutions.
BioDiagnostics, Inc. (BDI)
- Year: 2023
- Acquisition Price (USD millions): 20
- Strategic Rationale: Enhance its offering to dermatologists for treatment management of patients with suspicious moles.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has experienced significant revenue growth in recent years, driven by increased adoption of its DecisionDx-Melanoma and DecisionDx-SCC tests.
Future Projections: Analysts expect continued revenue growth, driven by expansion into new indications and penetration of existing markets. Profitability is expected to improve in the coming years.
Recent Initiatives: Acquisition of companies with complementary technologies and tests, expansion of sales and marketing efforts, and development of new tests for other cancer types.
Summary
Castle Biosciences is a growing diagnostics company specializing in genomic tests for cancer, primarily focusing on dermatology. Revenue growth is strong, but profitability remains a challenge. Key strengths are proprietary tests and clinical validation, but the company faces competition and reimbursement risks. Expansion into new indications and strategic acquisitions offer opportunities for future growth, but reimbursement policies are a threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Analyst Reports
- Yahoo Finance
- Company investor relations
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 784 | Website https://castlebiosciences.com |
Full time employees 784 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.